Eledon Pharmaceuticals Reports $39M Net Loss in Q1 2026, Focuses on Tegoprubart Development

Eledon Pharmaceuticals, Inc. reported a significant net loss of $39.0 million for the first quarter of 2026, compared to a net loss of $6.5 million during the same period in 2025. The company's total operating expenses increased to $21.2 million from $18.0 million year-over-year, primarily driven by a rise in research and development costs, which rose to $17.2 million from $13.5 million. This increase was largely attributed to heightened manufacturing expenses related to the production of clinical trial supplies for its lead compound, tegoprubart, as well as ongoing clinical development activities. General and administrative expenses saw a slight decrease, falling to $4.0 million from $4.4 million, reflecting reduced stock-based compensation costs.

Eledon's financial position showed a decline in cash and cash equivalents, which dropped to $6.2 million as of March 31, 2026, down from $22.8 million at the end of 2025. The company also reported total current assets of $113.6 million, a decrease from $135.7 million in the previous quarter. The accumulated deficit increased to $440.2 million, indicating ongoing challenges in achieving profitability. The company’s liabilities rose significantly, with warrant liabilities increasing to $30.4 million from $11.4 million, reflecting changes in the fair value of these financial instruments.

Strategically, Eledon continues to focus on the development of tegoprubart, an anti-CD40L antibody aimed at preventing organ rejection in kidney transplants and treating amyotrophic lateral sclerosis (ALS). The company has made progress in its clinical trials, including a Phase 1b study for kidney transplantation and a Phase 2 BESTOW trial, which is currently ongoing. Eledon has received regulatory approvals for these trials in multiple countries, including the U.S., Canada, and Australia. However, the company has indicated that it will require additional funding to continue its development efforts, particularly for ALS, as it has deprioritized its IgA nephropathy program.

Looking ahead, Eledon anticipates that its existing cash and short-term investments will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital to support its clinical programs and operational expenses. Eledon plans to explore various financing options, including public or private equity offerings and potential collaborations, to secure the necessary funds for its ongoing and future projects. The company remains committed to advancing its clinical programs while navigating the financial challenges inherent in the biotechnology sector.